Vipin Garg, Altimmune CEO

March 21, 2023 11:24 AM EDT

Altimmune’s shares halved after interim look at PhII weight loss drug data

Kyle LaHucik

Biotech Correspondent

Altimmune’s attempt to catch up to Novo Nordisk and Eli Lilly’s GLP-1 drugs hit an investor snag Tuesday after the biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Regeneron makes $80M obesity deal with Hansoh

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1B

DOGE set today as their last day at FDA. Instead, they're continuing to get full pay and don't work

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...